Investment Thesis
Sigyn Therapeutics is technically insolvent with negative stockholders' equity of -5.9M and faces an acute liquidity crisis (0.02x current ratio). Operating cash burn of -646.2K combined with minimal cash reserves of 85.6K and 3.5M debt burden indicates the company lacks sufficient financial resources to sustain operations beyond the near term. Despite 405% YoY revenue growth, absolute revenues (4.6K) are negligible and cannot offset -1.4M operating losses.
Strengths
- Positive gross margin of 55.1% suggests viable unit economics if revenue scales significantly
- Revenue growth of 405.6% YoY demonstrates some market traction and demand
- Company maintains minimal cash position of 85.6K
Risks
- Negative stockholders' equity of -5.9M indicates technical insolvency and balance sheet failure
- Critical liquidity crisis: 0.02x current ratio means only 2% of current liabilities covered by current assets
- Operating cash burn of -646.2K monthly against 85.6K cash reserves implies runway of approximately 1 week
- Long-term debt of 3.5M with total assets of only 135.6K creates unsustainable leverage
- Revenue base of 4.6K per period cannot support -1.4M operating expenses or debt service
- No insider Form 4 filings in past 90 days indicates lack of management confidence
Key Metrics to Watch
- Cash runway (days/weeks remaining at current burn rate)
- Debt restructuring, refinancing, or default status
- Absolute revenue levels and customer concentration
- Operating expense trajectory and path to profitability timeline
Financial Metrics
Revenue
4.6K
Net Income
-2.7M
EPS (Diluted)
$-1.68
Free Cash Flow
-647.1K
Total Assets
135.6K
Cash
85.6K
Profitability Ratios
Gross Margin
55.1%
Operating Margin
-30,546.9%
Net Margin
-58,785.5%
ROE
N/A
ROA
-1,990.3%
FCF Margin
-14,097.3%
Balance Sheet & Liquidity
Current Ratio
0.02x
Quick Ratio
0.01x
Debt/Equity
N/A
Debt/Assets
4,464.7%
Interest Coverage
-45.52x
Long-term Debt
3.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T21:57:18.310299 |
Data as of: 2025-09-30 |
Powered by Claude AI